Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 3, 2003, Pages 235-246

  Ali, Shadan ^a   Aranha, Olivia ^a   Li, Yiwei ^a   Pettit, George R ^b   Sarkar, Fazlul H ^a   Philip, Philip Agop ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Breast neoplasms; Bryostatin 1; Cell cycle; Gemcitabine; Protein kinase C

Indexed keywords

BRYOSTATIN 1; GEMCITABINE; ISOENZYME; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN P21; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL CYCLE; CELL STRAIN MCF 7; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MODULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL SURVIVAL; CYTOSOL; DEOXYCYTIDINE; DRUG SYNERGISM; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; ISOENZYMES; LACTONES; MACROLIDES; PROTEIN KINASE C; TUMOR CELLS, CULTURED;

EID: 0141787046     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0628-6     Document Type: Article

References (39)

1. Asaoka Y, Nakamura S, Yoshida K, and Nishizuka Y (1992) Protein kinase C, calcium and phospholipid degradation. Trends Biochem Sci 17:414
2. Barr LF, Campbell SE, Baylin SB (1997) Protein kinase C-beta 2 inhibits cycling and decreases c-myc-induced apoptosis in small cell lung cancer cells. Cell Growth Differ 8:381
3. Basu A, Lazo JS (1992) Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum (II) by bryostatin 1. Cancer Res 52:3119
4. Beltran PJ, Fan D, Fidler IJ, O'Brian CA (1997) Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation. Biochem Pharmacol 53:245
5. Bouffard DY, Momparler RL (1995) Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′ -difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res 19:849
6. Cabot MC, Zhang Z, Cao H, Lavie Y, Giuliano AE, Han TY, Jones RC (1997) Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation. Int J Cancer 70:567
7. Carmichael J, Mitchell JB, DeGraff WG, Gamson J, Gazdar AF, Johnson BE, Glatstein E, Minna JD (1985) Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer 57:540
8. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13:2731
9. Cartee L, Kucera GL (1998) Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells. Cancer Chemother Pharmacol 41:403
10. Cartee L, Kucera GL (2000) Protein kinase C modulation and anticancer drug response. Cancer Invest 18:731
11. Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ (1994) Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 63:2361
12. Deacon EM, Pongracz J, Griffiths G, Lord JM (1997) Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis (review). Mol Pathol 50:124
13. Frey MR, Saxon ML, Zhao X, Rollins A, Evans SS, Black JD (1997) Protein kinase C isozyme-mediated cell cycle arrest involves induction of p21 (waf1/cip1) and p27 (kip1) and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells. J Biol Chem 272:9424
14. Gordge PC, Hulme MJ, Clegg RA, Miller WR (1996) Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. Eur J Cancer 32A:2120
15. Grant S (1997) Modulation of ara-C induced apoptosis in leukemia by the PKC activator bryostatin 1. Front Biosci 2:d242
16. Grant S, Jarvis WD (1996) Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin Cancer Res 2:1915
17. Han EK, Cacace AM, Sgambato A, Weinstein IB (1995) Altered expression of cyclins and c-fos in R6 cells that overproduce PKC epsilon. Carcinogenesis 16:2423
18. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Statist 6:65
19. Huang P, Plunkett W (1995) Induction of apoptosis by gemcitabine. Semin Oncol 22:19
20. Itano Y, Ito A, Uehara T, Nomura Y (1996) Regulation of Bcl-2 protein expression in human neuroblastoma SH-SY5Y cells: positive and negative effects of protein kinases C and A, respectively. J Neurochem 67:131
21. Jarvis WD, Grant S (1999) Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs 17:227
22. Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, Pettit GR, Grant S (1994) Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 47:839
23. Jarvis WD, Fornari FA, Traylor RS, Martin HA, Kramer LB, Erukulla RK, Bittman R, Grant S (1996) Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. J Biol Chem 271:8275
24. Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52:23
25. Jeoung DI, Tang B, Sonenberg M (1995) Induction of tumor suppressor p21 protein by kinase inhibitors in MCF-7 cells. Biochem Biophys Res Commun 214:361
26. Kennedy MJ, Prestigiacomo LJ, Tyler G, May WS, Davidson NE (1992) Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res 52:1278
27. Mihalik R, Farkas G, Kopper L, Benczur M, Farago A (1996) Possible involvement of protein kinase C-epsilon in phorbol ester-induced growth inhibition of human lymphoblastic cells. Int J Biochem Cell Biol 28:925
28. Mohammad RM, al-Katib A, Pettit GR, Sensenbrenner LL (1994) Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res 54:165
29. O'Brian C, Vogel VG, Singletary SE, Ward NE (1989) Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 49:3215
30. Philip PA, Harris AL (1995) Potential for protein kinase C inhibitors in cancer therapy. In: Muggia FM (ed) Concepts, mechanisms, and new targets for chemotherapy (Cancer Treatment and Research, 78). Kluwer Academic Publishers, Boston, p 3
31. Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NS, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F, et al (1993) Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 85:1812
32. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M, et al (1993) A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68:418
33. Ruvolo PP, Deng X, Carr BK, May WS (1998) A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 273:25436
34. Schwaller J, Peters UR, Pabst T, Niklaus G, Macfarlane DE, Fey MF, Tobler A (1997) Up-regulation of p21WAF1 expression in myeloid cells is activated by the protein kinase C pathway. Br J Cancer 76:1554
35. Slosberg ED, Klein MG, Yao Y, Han EKH, Schieren I, Weinstein IB (1999) The alpha isoform of protein kinase C mediates phorbol ester-induced growth inhibition and p21(cip1) induction in HC11 mammary epithelial cells. Oncogene 18:6658
36. Stabel S (1994) Protein kinase C - an enzyme and its relatives. Semin Cancer Biol 5:277
37. Whelan RD, Parker PJ (1998) Loss of protein kinase C function induces apoptotic response. Oncogene 16:1934
38. Zonder J, Philip PA (1999) Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug. Expert Opin Invest Drugs. 8:2189
39. Zonder J, Shields AF, Zalupski M, Chaplen R, Heilbrun LK, Philip PA (2001) A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin Cancer Res 7:38